"“Patients can record and then forward to their doctors their temperature and heart and lung sounds, allowing doctors to listen for lung findings associated with pneumonia and asthma..."
"We of course know this is already out dated technology as ResApp is more accurate and requires no additional hardware."
On the contrary, this is a serious competitor. It provides more info to doctors, and the telehealth company might get a cut of the sale profits, making it attractive to both. Resapp will only be approved for two diseases in the beginning, whereas the above product will provide more info to diagnose a wide range of diseases.
- Forums
- ASX - By Stock
- RAP
- Dr Keating Email Interview
Dr Keating Email Interview, page-76
-
- There are more pages in this discussion • 32 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAP (ASX) to my watchlist
(20min delay)
|
|||||
Last
20.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $176.2M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
RAP (ASX) Chart |
Day chart unavailable
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, CEO
Anthony Noble
CEO
SPONSORED BY The Market Online